In the last trading session, 1.26 million Avidity Biosciences Inc (NASDAQ:RNA) shares changed hands as the company’s beta touched 0.93. With the company’s per share price at $30.22 changed hands at -$0.13 or -0.43% during last session, the market valuation stood at $3.64B. RNA’s last price was a discount, traded about -85.31% off its 52-week high of $56.00. The share price had its 52-week low at $21.51, which suggests the last value was 28.82% up since then.
Analysts gave the Avidity Biosciences Inc (RNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.07. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended RNA as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Instantly RNA was in red as seen at the end of in last trading. With action 3.03%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.92%, with the 5-day performance at 3.03% in the green. However, in the 30-day time frame, Avidity Biosciences Inc (NASDAQ:RNA) is 13.35% up.
The consensus price target for the stock as assigned by Wall Street analysts is 54.5, meaning bulls need an upside of 44.55% from its current market value. According to analyst projections, RNA’s forecast low is 50 with 59 as the target high. To hit the forecast high, the stock’s price needs a -95.23% plunge from its current level, while the stock would need to soar -65.45% for it to hit the projected low.
Avidity Biosciences Inc (RNA) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.37%. The 2025 estimates are for Avidity Biosciences Inc earnings to decrease by -36.98%, but the outlook for the next 5-year period is at -1.72% per year.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 10.2093% or 10.92 million shares worth $445.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund. With 4.43 shares estimated at $133.81 million under it, the former controlled 3.67% of total outstanding shares. On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund held about 2.93% of the shares, roughly 3.54 shares worth around $106.84 million.
